OBJECTIVE To investigate the role of clinical pharmacists in the anti-infective treatment of pulmonary mucormycosis secondary to a patient with myelodysplastic syndrome.

METHODS Clinical pharmacists participated in the anti-infective treatment practice of a patient with myelodysplastic syndrome who was transferred to the respiratory department due to secondary pulmonary mucormycosis, actively consulted the patient’s medical history and literature, participated in drug formulation and adjustment plan, and conducted pharmaceutical care and monitoring.

RESULTS In addition to the treatment of bacterial infections, the doctors took the advice of the clinical pharmacists to use posaconazole until the fungal species was determined. After confirming pulmonary mucormycosis infection, esaconazole combined with amphotericin B was adjusted according to liver function and prevent adverse reactions at the same time. After the treatments, the patient’s condition improved.

CONCLUSION Clinical pharmacists actively participate in the anti-mucor infection treatment process of the patient, put forward reasonable diagnosis and treatment suggestions, and implement medication monitoring and medication guidance for the patient, which ensure the safety and effectiveness of patient’s medication.